Literature DB >> 29290210

The most bothersome symptom of vaginal atrophy: Evidence from the observational AGATA study.

Federica Palma1, Anjeza Xholli1, Angelo Cagnacci2.   

Abstract

OBJECTIVES: Vaginal atrophy (VA) is a chronic medical condition. It is managed unsatisfactorily, despite its high prevalence and negative impact on female quality of life. In order to meet their needs, it would be useful to know what women perceive to be the most bothersome symptom (MBS) of VA. STUDY
DESIGN: Cross-sectional, multicenter study of 913 postmenopausal women consulting 22 gynecological outpatient services. MAIN OUTCOME MEASURES: Prevalence of the MBS perceived by postmenopausal women of different age and vaginal condition.
RESULTS: Vaginal dryness was the most prevalent MBS (54.4%), followed by dyspareunia (17.6%), itching (7.8%), dysuria (5.9%) and burning (2.0%). The prevalence of vaginal dryness as the MBS increased with years since menopause, while that of itching, dysuria and burning remained approximately constant over time. The prevalence of dyspareunia as the MBS was 26.2% in the first 6 years after menopause and declined thereafter, to 8.8%.
CONCLUSIONS: Among all postmenopausal women vaginal dryness per se, independent of dyspareunia, is the most commonly reported MBS. In each woman, the identification of the MBS may help to define more appropriate VA management.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  Dyspareunia; Genitourinary syndrome of menopause; Menopause; Post-menopause; Vaginal dryness

Mesh:

Year:  2017        PMID: 29290210     DOI: 10.1016/j.maturitas.2017.11.007

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  6 in total

1.  Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial.

Authors:  David F Archer; Steven R Goldstein; James A Simon; Arthur S Waldbaum; Steven A Sussman; Corrado Altomare; Julie Zhu; Yuki Yoshida; Sam Schaffer; Graziella Soulban
Journal:  Menopause       Date:  2019-01-28       Impact factor: 2.953

Review 2.  Treatment of genitourinary syndrome of menopause: the potential effects of intravaginal ultralow-concentration oestriol and intravaginal dehydroepiandrosterone on quality of life and sexual function.

Authors:  Valentina Lucia La Rosa; Michał Ciebiera; Li-Te Lin; Shangrong Fan; Salvatore Butticè; Thozhukat Sathyapalan; Robert Jędra; Patricia Lordelo; Alessandro Favilli
Journal:  Prz Menopauzalny       Date:  2019-06-28

3.  Effects of ospemifene on genitourinary health assessed by prospective vulvar-vestibular photography and vaginal/vulvar health indices.

Authors:  Irwin Goldstein; James A Simon; Andrew M Kaunitz; Corrado Altomare; Yuki Yoshida; Julie Zhu; Sam Schaffer; Graziella Soulban
Journal:  Menopause       Date:  2019-09       Impact factor: 2.953

Review 4.  Ospemifene in the Management of Vulvar and Vaginal Atrophy: Focus on the Assessment of Patient Acceptability and Ease of Use.

Authors:  Angelo Cagnacci; Anjeza Xholli; Martina Venier
Journal:  Patient Prefer Adherence       Date:  2020-01-10       Impact factor: 2.711

Review 5.  Modern management of genitourinary syndrome of menopause.

Authors:  Ana Sofia Da Silva; Georgina Baines; George Araklitis; Dudley Robinson; Linda Cardozo
Journal:  Fac Rev       Date:  2021-03-03

Review 6.  Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women.

Authors:  Rossella E Nappi; Ellis Martini; Laura Cucinella; Silvia Martella; Lara Tiranini; Alessandra Inzoli; Emanuela Brambilla; David Bosoni; Chiara Cassani; Barbara Gardella
Journal:  Front Endocrinol (Lausanne)       Date:  2019-08-21       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.